Search results
Showing 2656 to 2670 of 8929 results
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Empagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Canagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Dapagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Narcolepsy with or without cataplexy in adults: pitolisant (ES8)
Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making